



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF:

Mantell et al.

SERIAL NO.: 09/590,585

FILED: June 8, 2000

FOR: Purine Derivatives  
-----

Assistant Commissioner for Patents  
Washington, DC 20231

: EXAMINER: Patrick Lewis

: I hereby certify that this correspondence  
: is being deposited with the United States  
: Postal Service as First Class Mail in an  
: envelope addressed to: Assistant Commissioner  
: for Patents, Washington, D.C. 20231 on

this 10<sup>th</sup> day of March 2003

Sir:

By 

RESPONSE UNDER 35 U.S.C. §1.111 AND U.S.C. §1.21

This is in response to the Office Action mailed February 11, 2003 in the subject patent application. The term for responding to this Office Action was set to expire one month from February 11, 2003, i.e., on March 11, 2003. Accordingly, this response is being timely filed.

- Amendments -

Please amend the application as follows:

In the claims:

Cancel claims 25 - 29 and 31 - 42, without waiver or prejudice. Applicants reserve the right to file divisional applications directed to the nonelected subject matter of this application.

-Remarks-

Amendments.

Applicants have amended the application herein to remove all subject matter not within the scope of elected Group I. Accordingly, the only claims remaining in the application are claims 1 - 18 and 30, claims 19 - 24 having been canceled in Applicants' previous response dated November 18, 2002.

Election Requirement.

The Examiner has required Applicants to elect a single species drawn to one of the compounds disclosed on pages 43 - 75 of the specification. The compounds disclosed on pages 43 - 75 correspond to the compounds of Preparations 1 through 29. Applicants submit that all of those compounds, i.e., the compounds of Preparations 1 through 29, are intermediates used in preparing the compounds of Formula I of claim 1. None of those compounds are within the scope of Claim 1 or of elected Group I.